期刊文献+

短刺小克银汉霉AS3.910的CYP2C9同工酶抑制作用

The inhibition of CYP2C9 isoenzyme in Cunninghamella blakesleeana AS 3.910
下载PDF
导出
摘要 目的探索具有药物代谢酶CYP2C9活性的微生物模型对CYP2C9抑制剂的响应。方法选用短刺小克银汉霉AS 3.910为模型菌株,检测CYP2C9抑制剂对CYP2C9底物特定转化产物产率的影响,并通过底物间相互影响的程度探索该转化体系中的药物代谢相互作用。采用液相色谱-多级质谱联用技术检测转化产物。结果CYP2C9抑制剂苯溴马隆抑制4′-羟基甲苯磺丁脲的生成,使其产率由100%下降到14.5%;磺胺苯吡唑抑制O-去甲基吲哚美辛的生成,使其产率由75.2%降低到9.9%;丙戊酸抑制4′-羟基双氯芬酸的生成,使其产率由98.6%降低到2.7%。底物药物甲苯磺丁脲、双氯芬酸和吲哚美辛之间存在代谢相互作用,导致生成相应代谢物的产率降低。结论3种CYP2C9抑制剂不同程度地抑制了短刺小克银汉霉的CYP2C9同工酶,而且CYP2C9底物间存在药物代谢相互作用。 Aim To investigate the variation of CYP2C9 isoenzyme activity in the microbial model in response to inhibitors of CYP2C9. Methods Using C. blakesleeana AS 3. 910 as a model strain, the impact of CYP2C9 inhibitors on the metabolites yields of CYP2C9 substrates was determined and the drugdrug interactions among CYP2C9 substrates were evaluated. Liquid chromatography-mass spectrometry was used to analyze biotransformation products. Results Benzbromarone decreased the yield of 4'- hydroxytolbutamide from 100% to 14.5% ; sulfaphenazole decreased the yield of O-demethylindomethacin from 75.2% to 9.9% ; valproic acid decreased the yield of 4'-hydroxydiclofenac from 98.6% to 2.7% , separately. Tolbutamide, indomethacin and diclofenac interacted with each other, resulting in the decreased formation of metabolites catalyzed by CYP2C9. Conclusion Three CYP2C9 inhibitors inhibit the activity of CYP2C9 isoenzyme in C. blakesleeana AS 3. 910 differently, and there are drug-drug interactions among CYP2C9 substrates.
出处 《药学学报》 CAS CSCD 北大核心 2006年第10期967-972,共6页 Acta Pharmaceutica Sinica
基金 国家高技术研究发展计划(863计划)资助项目(2005AA2Z3C70).
关键词 细胞色素P450 CYP2C9 短刺小克银汉霉 药物代谢 同工酶 酶抑制剂 cytochrome P450 CYP2C9 Cunninghamella blakesleeana drug metabolism isoenzyme enzyme inhibitor
  • 相关文献

参考文献17

  • 1Azerad R.Microbial models for drug metabolism[J].Adv Biochem Eng Bioteehnol,1999,63:169 -218.
  • 2Zhong DL,Yang YF,Julian EA,et al.Phase I and Phase Ⅱ enzymes produced by Cunninghamella elegans for the metabolism of xenobiotics[J].FEMS Microbiol Lett,1996,138:221 -226.
  • 3Srisilam K,Veeresham C.Biotransformation of drugs by microbial cultures for predicting mammalian drug metabolism[J].Biotechnol Adv,2003,21:3-39.
  • 4杨秀伟,黄海华,张鹏,林立红,钟大放.建立具有药物代谢酶CYP2C9活性的微生物模型[J].中国药学杂志,2006,41(7):551-555. 被引量:1
  • 5Yuan R,Madani S,Wei XX,et al.Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions[J].Drug Metab Dispos,2002,30:1311 -1319.
  • 6Dorado P,Berecz R,Caceres MC,et al.Analysis of diclofenac and its metabolites by high-performance liquid chromatography:relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios[J].J Chromatogr B Analyt Technol Biomed Life Sci,2003,789:437 -442.
  • 7Nakajima M,Inoue T,Shimada N,et al.Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes[J].Drug Metab Dispos,1998,26:261 -266.
  • 8Mancy A,Dijols S,Poli S,et al.Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C:molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP2C9[J].Biochemistry,1996,35:16205-16212.
  • 9Locuson CW,Wahlstrom JL,Rock DA,et al.A new class of CYP2C9 inhibitors:probing 2C9 specificity with high-affinity benzbromarone derivatives[J].Drug Metab Dispos,2003,31:967 -971.
  • 10Wen X,Wang JS,Kivisto KT,et al.In vitro evaluation of valproic acid as an inhibitior of human cytochrome P450 isoforms:preferential inhibition of cytochrome P450 2C9 (CYP2C9)[J].Br J Clin Pharmacol,2001,52:547-553.

二级参考文献12

  • 1Ai Ping BAI,Zong Ru GUO,Wen Hui HU,Fang SHEN,Gui Fang CHENG.Design,Synthesis and in vitro Evaluation of a New Class of Novel Cyclooxygenase-2 Inhibitors:3,4-diaryl-3-pyrrolin-2-ones[J].Chinese Chemical Letters,2001,12(9):775-778. 被引量:7
  • 2SRISILAM K,VEERESHAM C.Biotransformation of drugs by microbial cultures for predicting mammalian drug metabolism[J].Biotechnol Adv,2003,21(1):3-39.
  • 3ZHANG D L,YANG Y F,LEAKEY E A,et al.Phase Ⅰ and Phase Ⅱ enzymes produced by Cunninghamella elegans for the metabolism of xenobiotics[J].FEMS Microbiol Lett,1996,138:221-226.
  • 4WACKETT L P,GIBSON D T.Metabolism of xenobiotic compounds by enzymes in cell extracts of the fungus Cunninghamella elegans[J].Biochem J,1982,205(1):117-122.
  • 5HUANG H H,CHEN X Y,ZHONG D F.Selective biotransformation of propafenone by Cunninghamella blakesleana[J].Asian J Drug Metab Pharmocokinet,2001,1 (1):37-43.
  • 6WEBSTER R,PACEY M,WINCHESTER T,et al.Microbial oxidative metabolism of diclofenac:production of 4'-hydroxydiclofenac using Epiccocum nigrum IMI354292[J].Appl Microbiol Biotechnol,1998,49(4):371-376.
  • 7KIM K A,PARK J Y.Inhibitory effect of glyburide on human cytochrome P450 isoforms in human liver microsomes[J].Drug Metab Dispos,2003,31(9):1090-1092.
  • 8LEEMAN T,TRANSON C,DAYER P.Cytochrome P450TB (CYP2C):A major monooxygenase catalysing diclofenacs 4'-hydroxylation in human liver[J].Life Sci,1993,52:29-34.
  • 9NAKAJIMA M,INOUE T,SHIMADA N,et al.Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes[J].Drug Metab Dispos,1998,26(3):261-266.
  • 10SCHWARZ U L.Clinical relevance of genetic polymorphisms in the human CYP2C9 gene[J].Eur J Clin Invest,2003,33(suppl 2):23-30.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部